Nasdaq · Biotech stocks database

ICLR — ICON plc

ICLR (ICON plc) stock: $164.11, $12.57B market cap, $647.3M cash, $15.72B EV, $12.57B fully diluted market cap. Data from Fully Diluted's biotech stocks database.

Share price

$164.11

Market cap

$12,565.5M

Cash

$647.3M

Enterprise value

$15,724.4M

Balance sheet

Cash	$647.3M
Debt	$3,806.2M
Net cash	-$3,158.9M
Enterprise value	$15,724.4M
Basic shares	76.6M shares
Fully diluted shares	76.6M shares
Fully diluted market cap	$12,565.5M
Cash per share	$8.45

Cash figures as of 2025-12-31. Database snapshot: 2026-09-21.

Price history

Loading ICLR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 11 - Feb 22	Jynneos	Phase 2	Monkeypox (Mpox)	—
Nov 12 - Dec 24	SP-420	Phase 2	Beta Thalassemia Major Anemia; Myelodysplastic Syndrome	—
Mar 9 - Apr 20	Anifrolumab	Phase 3	Systemic Lupus Erythematosus	—
Apr 11 - May 23	Camizestrant	Phase 3	ER-Positive HER2-Negative Breast Cancer	—
Nov 8 - Dec 20	Belimumab	Phase 3	Connective Tissue Diseases	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05710692	Phase 3	Recruiting	Collaborator	Chiesi Farmaceutici S.p.A.	—	Fabry Disease	—
NCT06328608	Phase 3	Recruiting	Collaborator	Chiesi Farmaceutici S.p.A.	—	Fabry Disease	—
NCT07430306	Phase 3	Recruiting	Collaborator	AZN	AZN	Systemic Lupus Erythematosus	—
NCT07647328	Phase 3	Recruiting	Collaborator	AZN	AZN	ER-Positive HER2-Negative Breast Cancer	—
NCT06716606	Phase 3	Recruiting	Collaborator	GSK	GSK	Connective Tissue Diseases	—
NCT04620239	Phase 3	Active, not recruiting	Collaborator	Steba Biotech S.A.	—	Transitional Cell Cancer of Renal Pelvis and Ureter	—
NCT03513939	Phase 2	Active, not recruiting	Collaborator	Sernova Biotherapeutics Inc.	—	Type 1 Diabetes Mellitus	—
NCT07199569	Phase 2	Active, not recruiting	Collaborator	Bavarian Nordic	—	Monkeypox (Mpox)	—
NCT05693909	Phase 2	Recruiting	Collaborator	Pharmacosmos A/S	—	Beta Thalassemia Major Anemia; Myelodysplastic Syndrome	—
NCT07514338	Phase 2	Not yet recruiting	Collaborator	Pharming Technologies B.V.	—	Mitochondrial Diseases	—
NCT04844866	Phase 2	Recruiting	Collaborator	Miltenyi Biomedicine GmbH	—	Diffuse Large B-cell Lymphoma	—
NCT05997264	Phase 2	Active, not recruiting	Collaborator	Biomedical Advanced Research and Development Authority	—	Anthrax	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 23 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 23 active trials for Chiesi Farmaceutici S.p.A. on ClinicalTrials.gov

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego